Phaseline

Companies › SparingVision

SparingVision: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Ophthalmology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SPVN06
AAV-delivered RdCVF-RdCVFL gene therapy
RDCVFPhase 1Retinitis PigmentosaFeb 2027
SPVN20
Gene therapy for rod-cone dystrophy
–Phase 1Retinitis Pigmentosa (RP)Mar 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05748873SPVN06Phase 1Retinitis PigmentosaOphthalmologyFeb 2027
NCT07807111SPVN20Phase 1Retinitis Pigmentosa (RP)OphthalmologyMar 2032

Targets

RDCVF (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.